Date: 2012-05-24
Type of information:
phase: 3
Announcement:
Company: PharmaNeuroBoost (Belgium)
Product: PNB01
Action mechanism: PNB01 is the fixed dose combination of citalopram (Selective Serotonin Reuptake Inhibitors (SSRI) ) and low dose pipamperone (neuroleptic agent).
Disease: major depressive disorder (MDD)
Therapeutic area: CNS diseases - Mental diseases
Country: USA, Canada
Trial details:
Latest
news: PharmaNeuroBoost has announced that already 250 out of 555 patients have been recruited and treated in the PNB01 Phase III Program. These patients are being treated in the 32 American and Canadian centers participating in the study.
